Petros Grivas(@PGrivasMDPhD) 's Twitter Profileg
Petros Grivas

@PGrivasMDPhD

Oncologist, Professor, clinical/translational research, Genitourinary Cancers, bladder, prostate, testis, Univ of Washington, Fred Hutch; views are mine

ID:3379037548

linkhttps://www.seattlecca.org/physicians/petros-grivas calendar_today16-07-2015 16:21:53

18,0K Tweets

16,5K Followers

11,9K Following

Follow People
Adam Sowalsky(@sowalsky) 's Twitter Profile Photo

In the inaugural NIH Liquid Biopsy conference was a two-day meeting consisting of lectures, posters, breakout sessions and roundtable discussions. Thank you to our speakers for making it successful! NIH Intramural NCI Center for Cancer Research NIH NHLBI NIH National Cancer Institute NICHD News NHLBI Bethesda Labs

In the inaugural NIH Liquid Biopsy conference was a two-day meeting consisting of lectures, posters, breakout sessions and roundtable discussions. Thank you to our speakers for making it successful! @IRPatNIH @NCIResearchCtr @nih_nhlbi @NIH @theNCI @NICHD_NIH @TheBethesdaLabs
account_circle
Karen Knudsen, MBA PhD(@AmerCancerCEO) 's Twitter Profile Photo

Transportation and lodging are key determinants of whether or not patients are able to complete their cancer care. By providing grant funding, the American Cancer Society Society is working to address these and improve cancer outcomes for all patients.

account_circle
Lynn M. Schuchter, MD, FASCO(@ASCOPres) 's Twitter Profile Photo

convenes such a passionate community of cancer care professionals focused on advancing quality, safety, & efficiency in care delivery.

Don’t miss your chance to present your research at this dynamic, interdisciplinary forum—submit your abstract by 5/21.

account_circle
Cancer Discovery(@CD_AACR) 's Twitter Profile Photo

Watch first author Sumanta K. Pal (Sumanta K. Pal, MD, FASCO) discuss his research article, CD70-Targeted Allogeneic CAR T-Cell Therapy for Advanced Clear Cell Renal Cell , published simultaneously at :
vimeo.com/932606570/8875…
City of Hope

account_circle
Toni Choueiri, MD(@DrChoueiri) 's Twitter Profile Photo

schedule alert!  Take a break and join us outside in the ASCO Garden (D2 Terrace) June 1st, 2 PM CST to watch Borussia Dortmund take on Real Madrid C.F. in the UEFA Champions League Final!!!

#ASCO24 schedule alert!  Take a break and join us outside in the @ASCO Garden (D2 Terrace) June 1st, 2 PM CST to watch @BVB take on @realmadrid in the @UEFA Champions League Final!!!
account_circle
Brian Rini, MD(@brian_rini) 's Twitter Profile Photo

Amazing RCC-related didactic videos from the Academy of Kidney Cancer Investigators are available at:
youtube.com/@AcademyofKidn…

Check them out!

account_circle
Mohammad Jad Moussa, MD, MSc(@mjmoussa_) 's Twitter Profile Photo

🙌Gearing up for w/ our Poster Presentation in Cancer – Kidney & Bladder Session

👉Looking forward to linking up w/ thought leaders & fellows, as we unravel groundbreaking insights & tackle unmet needs in ! Omar Alhalabi, MD Matt Campbell MD, MS MD Anderson Cancer Center

🙌Gearing up for #ASCO24 w/ our Poster Presentation in #GU Cancer – Kidney & Bladder Session 👉Looking forward to linking up w/ thought leaders & fellows, as we unravel groundbreaking insights & tackle unmet needs in #BladderCancer! @OAlhalabiMD @DocMattCampbell @MDAndersonNews
account_circle
Enrique Grande(@drenriquegrande) 's Twitter Profile Photo

🔘 Out on The Lancet Oncology Pembrolizumab monotherapy for high-risk non-muscle-invasive bladder cancer without carcinoma in situ and unresponsive to BCG (KEYNOTE-057): a single-arm, multicentre, phase 2 trial

Andrea Necchi Ashish M. Kamat, MD, MBBS Petros Grivas

🔘 Out on @TheLancetOncol Pembrolizumab monotherapy for high-risk non-muscle-invasive bladder cancer without carcinoma in situ and unresponsive to BCG (KEYNOTE-057): a single-arm, multicentre, phase 2 trial #BladderCancer #Immunotherapy @AndreaNecchi @UroDocAsh @PGrivasMDPhD…
account_circle
OncoAlert(@OncoAlert) 's Twitter Profile Photo

The OncoAlert🚨ROUND UP
Covering May 2-8, 2024

REGISTER at OncoAlert360.com OR oncoalert.m-pages.com/nhMpwe/oncoale…

The Lancet Commission on
thelancet.com/journals/lance…

✅DESTINY-PanTumor01
thelancet.com/journals/lanon…

✅MONARCH3 🦋in

account_circle
Andrea Necchi(@AndreaNecchi) 's Twitter Profile Photo

📬 Finally out in The Lancet Oncology the results from Cohort B of KN057 trial. Pembro in BCG-unresponsive papillary tumors w/out Cis. 43% 12m DFS adds a Rx piece to the literature. Now included in National Comprehensive Cancer Network (NCCN) guidelines. Congrats Ashish M. Kamat, MD, MBBS Petros Grivas & team! sciencedirect.com/science/articl…

📬 Finally out in @TheLancetOncol the results from Cohort B of KN057 trial. Pembro in BCG-unresponsive papillary tumors w/out Cis. 43% 12m DFS adds a Rx piece to the literature. Now included in @NCCN guidelines. Congrats @UroDocAsh @PGrivasMDPhD & team! sciencedirect.com/science/articl…
account_circle
UroToday.com(@urotoday) 's Twitter Profile Photo

Advancements in cutting-edge SABR therapy for oligometastatic . Shankar Siva Peter Mac Cancer Centre joins Alicia Morgans, MD, MPH Dana-Farber to discuss the innovative use of this therapy and its effectiveness in achieving local control > bit.ly/3WbPbyL

Advancements in cutting-edge SABR therapy for oligometastatic #KidneyCancer. @_ShankarSiva @PeterMacCC joins @CaPsurvivorship @DanaFarber to discuss the innovative use of this therapy and its effectiveness in achieving local control > bit.ly/3WbPbyL
account_circle